Canada - TSX-V:XRTX - CA98420Q3061 - Common Stock
The current stock price of XRTX.CA is 1.22 CAD. In the past month the price decreased by -3.17%. In the past year, price decreased by -41.9%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
BHC.CA | BAUSCH HEALTH COS INC | 1.78 | 3.45B | ||
TLRY.CA | TILRAY BRANDS INC | N/A | 1.93B | ||
CRON.CA | CRONOS GROUP INC | 52 | 1.39B | ||
DHT-UN.CA | DRI HEALTHCARE TRUST | 6.6 | 783.15M | ||
GUD.CA | KNIGHT THERAPEUTICS INC | N/A | 601.89M | ||
DHT-U.CA | DRI HEALTHCARE TRUST | 4.89 | 580.05M | ||
WEED.CA | CANOPY GROWTH CORP | N/A | 486.98M | ||
HITI.CA | HIGH TIDE INC | N/A | 435.40M | ||
CPH.CA | CIPHER PHARMACEUTICALS INC | 25.42 | 411.96M | ||
TSND.CA | TERRASCEND CORP | N/A | 399.32M | ||
ACB.CA | AURORA CANNABIS INC | N/A | 390.38M | ||
OGI.CA | ORGANIGRAM GLOBAL INC | N/A | 334.48M |
XORTX Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Calgary, Alberta. The company went IPO on 2015-09-30. The firm is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. The company has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. The company is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
XORTX THERAPEUTICS INC
3710 - 33rd Street NW
Calgary ALBERTA CA
Employees: 3
Phone: 14034557727
The current stock price of XRTX.CA is 1.22 CAD. The price increased by 9.91% in the last trading session.
The exchange symbol of XORTX THERAPEUTICS INC is XRTX and it is listed on the TSX Venture Exchange exchange.
XRTX.CA stock is listed on the TSX Venture Exchange exchange.
XORTX THERAPEUTICS INC (XRTX.CA) has a market capitalization of 6.36M CAD. This makes XRTX.CA a Nano Cap stock.
XORTX THERAPEUTICS INC (XRTX.CA) currently has 3 employees.
XORTX THERAPEUTICS INC (XRTX.CA) has a support level at 1.22 and a resistance level at 1.25. Check the full technical report for a detailed analysis of XRTX.CA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
XRTX.CA does not pay a dividend.
XORTX THERAPEUTICS INC (XRTX.CA) will report earnings on 2025-11-12.
XORTX THERAPEUTICS INC (XRTX.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.4).
ChartMill assigns a fundamental rating of 2 / 10 to XRTX.CA. While XRTX.CA has a great health rating, there are worries on its profitability.
Over the last trailing twelve months XRTX.CA reported a non-GAAP Earnings per Share(EPS) of -0.4. The EPS increased by 79.15% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -28.38% | ||
ROE | -36.23% | ||
Debt/Equity | 0 |